0
Deep & Emerging Tech·November 11, 2026·1 min read

AlphaGenome 2: Deciphering how cells read DNA to better understand disease

Share

AlphaGenome 2 pushes AI deeper into regulatory genomics — from reading DNA to modeling how specific cell types interpret it. For biotech and pharma, this tightens the feedback loop between variant interpretation and target discovery, and raises the bar for in-house modeling teams.

Deep & Emerging Tech

OKX and ICE's joint venture OKXICE plans to launch a US tokenized stock venue on November 23 and list 70+ assets; 56 of the 62 companies it targeted objected

Tokenized equities are running straight into issuer resistance—56 of 62 targeted companies objected—which means the near-term action will be in regulatory arbitrage and niche assets, not blue-chip stocks. If you’re a broker or exchange operator, treat tokenization as an infrastructure experiment for now, not a core revenue line.